What is it about?
We studied if changes in the type of dietary fatty acids could decrease or improve digestibility and affect gastrointestinal side effects of Pirfenidone
Featured Image
Why is it important?
Gastrointestinal adverse events associated to pirfenidone in IPF patients are the main reason for discontinuation of anti-fibrotic medication. Maintaining patients on treatment would benefit on disease behaviour, so any improvements we can make in this way are important.
Perspectives
Monounsaturated Fatty Acid diet associates a lower rate of gastrointestinal adverse events associated to Pirfenidone than diet predominant in saturated fatty acids, so modifying the diet we could improve Pirfenidone tolerance. It would be interesting to keep searching in this area if different changes in diet (such as polyunsaturated fatty acid, probiotics ...) can make changes in Pirferidone tolerance.
EVA FONTANILLES
Institut d'Investigacio Biomedica de Bellvitge
Read the Original
This page is a summary of: Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial, September 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2020.3712.
You can read the full text:
Contributors
The following have contributed to this page
